Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 4/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9994907 | 0.83 | NOTUM (0.39) | HPGDGAAALDH1A1RAB9A | |
| SCHEMBL9995101 | 0.81 | GPR119 (0.46) | PDK2HPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL19265536 | 0.78 | CNR2 (0.50) | PDK2CNR1CNR2HPGDMEN1 | |
| SCHEMBL742645 | 0.72 | RAB9A (0.42) | HPGDMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL11319421 | 0.70 | ALDH1A1 (0.44) | GAAALDH1A1SMN1; SMN2TSHRRAB9A | |
| SCHEMBL4713689 | 0.70 | SMN1; SMN2 (0.38) | S1PR1S1PR5CNR1CNR2HPGD | |
| SCHEMBL19520284 | 0.69 | PDK2 (0.65) | PDK2HPGDMEN1KMT2AGAA | |
| SCHEMBL11314703 | 0.68 | ALDH1A1 (0.41) | GAAALDH1A1SMN1; SMN2TSHRRAB9A | |
| SCHEMBL11030370 | 0.67 | ALOX5 (0.46) | HPGDMEN1KMT2AGAAALDH1A1 | |
| SCHEMBL2569062 | 0.67 | DPP4 (0.39) | PDK2MEN1KMT2AGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946230-B2 | Aryl- and heteroaryl- nitrogen-heterocyclic compounds as PDE10 inhibitors | AMGEN INC. (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2569299-A1 | NITROGEN- HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2013-03-20 | — | — | EP | disclosed |
| US-20110306590-A1 | ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| WO-2011143129-A1 | NITROGEN- HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306590-A1 | ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS | HDAC10, PDE10A, PDE9A | PDK2 434/4885S1PR1 4017/4885S1PR5 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.